IKT
Inhibikase Therapeutics, Inc. - Common Stock (IKT)
$20
About Inhibikase Therapeutics, Inc. - Common Stock (IKT)
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in development of protein kinase inhibitor therapeutics to modify the course of Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. It also focuses on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Ableson Tyrosine Kinases. The company was founded by Milton H. Werner in September 2008 and is headquartered in Wilmington, DE.
Details
Daily high
$2.32
Daily low
$2.20
Price at open
$2.31
52 Week High
$2.61
52 Week Low
$1.33
Market cap
320.9M
Dividend yield
-
Volume
365,996
Avg. volume
540,873
P/E ratio
-5.27
Inhibikase Therapeutics, Inc. - Common Stock News
Details
Daily high
$2.32
Daily low
$2.20
Price at open
$2.31
52 Week High
$2.61
52 Week Low
$1.33
Market cap
320.9M
Dividend yield
-
Volume
365,996
Avg. volume
540,873
P/E ratio
-5.27